


**Product Name** : LXH254  
**Cat. No.** : PC-35635  
**CAS No.** : 1800398-38-2  
**Molecular Formula** : C<sub>25</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>  
**Molecular Weight** : 502.494  
**Target** : Raf  
**Solubility** : 10 mM in DMSO



## Biological Activity

LXH254 (Naporafenib, LXH 254) is a highly potent, selective B/C **RAF** inhibitor with K<sub>d</sub> of 1.3/3.6 nM respectively, shows less activity against ARAF.

LXH254 (Naporafenib) inhibits pMEK and cell proliferation in Calu-6 cells with EC<sub>50</sub> of 0.014 uM and 0.47 uM, respectively

LXH254 (Naporafenib) showed a high level of selectivity on a panel of 456 kinases, demonstrating greater than 98% on-target binding to BRAF, BRAFV600E, and CRAF at 1 uM and very few off-targets, with DDR1 (>99%), DDR2 (84%), and PDGFRb (>99%) the only kinases with binding >80% at 1 uM.

LXH254 (Naporafenib) was active in models harboring BRAF alterations, including atypical BRAF alterations coexpressed with mutant K/NRAS, and NRAS mutants, but had only modest activity in KRAS mutants. LXH254 caused paradoxical activation of MAPK signaling in a manner similar to dabrafenib in cells expressing only ARAF.

LXH254 (Naporafenib) demonstrated tumor regression in the Calu-6 xenograft nude rat model.

## References

- Monaco KA, et al. *Clin Cancer Res*. 2021 Apr 1;27(7):2061-2073.
- Ramurthy S, et al. *J Med Chem*. 2020 Mar 12;63(5):2013-2027.
- Negrão MV, et al. *J Thorac Oncol*. 2020 Oct;15(10):1611-1623.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com